摘要
目的利用PrP106-126多肽感染的SH-SY5Y细胞,探究黄芩素对PrP106-126引起的神经毒性保护作用及其机制。方法将SH-SY5Y细胞按照不同的处理分成细胞对照组、药物对照组、PrP106-126对照组、PrPScr对照组、黄芩素作用组。采用细胞病变法及MTT法检测PrP106-126对SH-SY5Y细胞形态和活性的影响,采用MTT法检测黄芩素抑制PrP106-126多肽神经毒性的药效,TUNEL法检测黄芩素对PrP106-126多肽所致细胞凋亡的影响。结果与细胞对照组比较,PrP106-126感染的SH-SY5Y细胞形态明显不同,可见细胞折光性变强,细胞聚集呈破碎样。与PrPScr对照组比较,PrP106-126感染的细胞抑制率显著升高,差异有统计学意义(P<0.05)。与PrP106-126对照组比较,在治疗模式和预防模式中黄芩素作用组细胞增殖率明显升高,差异有统计学意义(P<0.05)。与细胞对照组比较,PrP106-126对照组的细胞凋亡指数(AI)明显升高(P<0.01);与PrP106-126对照组比较,黄芩素作用组的细胞AI明显降低(P<0.05)。结论黄芩素在体外对朊病毒具有治疗和预防作用,其作用机制可能与细胞凋亡有关。
Objective To explore the protective effect of baicalein on neurotoxicity induced by PrP106-126 and its mechanism.Methods SH-SY5Y cells were divided into cell control group,drug control group,PrP106-126 control group,PrPScr control group and baicalein treatment group according to different treatments.Cytopathic method and MTT were used to detect the effect of PrP106-126 on the morphology and activity of SH-SY5Y cells.The MTT assay was used to detect the efficacy of baicalein in inhibiting the neurotoxicity of PrP106-126.The effect of baicalein on apoptosis induced by PrP106-126 polypeptide was detected by TUNEL.Results The morphology of SH-SY5Y cells infected with PrP106-126 was significantly different from that of cell control.It was found that the photorefractive cells became stronger and the aggregation of cells was broken.Compared with PrPScr control group,the inhibition rate of PrP106-126 was significantly higher(P<0.05).Compared with PrP106-126 control group,the cell increment rate of baicalein group in the treatment and prevention models was increased significantly(P<0.05).Compared with cell control group,cell apoptotic index(AI)of PrP106-126 group was significantly higher(P<0.01).Compared with PrP106-126 control group,cell AI of baicalin treated group was decreased significantly(P<0.05).Conclusion Baicalein has a therapeutic and prophylactic effects on prions in vitro,and its mechanism may be related to apoptosis.
作者
秦笙
彭健愉
柏彩英
郑水兰
蓝锴
曹楠楠
程招敏
周强
QIN Sheng;PENG Jianyu;BAI Caiying;ZHENG Shuilan;LAN Kai;CAO Nannan;CHENG Zhaomin;ZHOU Qiang(Department of Clinical Laboratory,Guangdong Provincial Hospital of Traditional Chinese Medicine,Guangdong Province,Guangzhou 510120,China;Department of Clinical Laboratory,Guangdong Women and Children Hospital,Guangdong Province,Guangzhou 511400,China;Guangzhou Huiguanglin Technology Limited Company,Guangdong Province,Guangzhou 510032,China)
出处
《中国医药导报》
CAS
2019年第34期7-10,I0002,共5页
China Medical Herald
基金
广东省医学科学技术研究基金项目(A2018210)
广东省中医院中医药科学技术研究专项课题(YN2016QJ09)